Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29520417 | 0.97 | KISS1R (0.65) | KISS1R | |
| SCHEMBL29978342 | 0.95 | KISS1R (0.63) | KISS1R | |
| SCHEMBL30276212 | 0.91 | KISS1R (0.62) | KISS1RIL23R | |
| SCHEMBL30874654 | 0.91 | KISS1R (0.57) | KISS1R | |
| SCHEMBL30823583 | 0.91 | KISS1R (0.71) | KISS1R | |
| SCHEMBL29464013 | 0.90 | NPY4R (0.55) | KISS1R | |
| SCHEMBL30168673 | 0.90 | KISS1R (0.67) | KISS1R | |
| SCHEMBL31665973 | 0.90 | GLP1R (0.65) | KISS1RIL23R | |
| SCHEMBL31314991 | 0.89 | KISS1R (0.61) | KISS1R | |
| SCHEMBL29555876 | 0.89 | GLP1R (0.60) | KISS1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541402-B1 | C3A RECEPTOR AGONISTS FOR USE AGAINST ISCHEMIC BRAIN INJURY | PEKNA MARCELA (SE) | 2022-07-20 | — | — | EP | claimed |
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-19 | — | — | US | claimed |
| US-11266715-B2 | C3A receptor agonists for use against ischemic brain injury, stroke, traumatic brain injury, spinal cord injury and neurodegenerative disorders | PEKNA MARCELA (SE) | 2022-03-08 | — | — | US | claimed |
| EP-3377104-B1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3541402-B1 | C3A RECEPTOR AGONISTS FOR USE AGAINST ISCHEMIC BRAIN INJURY | PEKNA MARCELA (SE) | 2022-07-20 | — | — | EP | disclosed |
| CN-108472370-B | Modulating blood cerebrospinal fluid barrier permeability | 纪念斯隆-凯特琳癌症中心 | 2022-07-12 | — | — | CN | disclosed |
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-19 | — | — | US | disclosed |
| US-11305014-B2 | Modulating permeability of the blood cerebrospinal fluid barrier | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-04-19 | — | — | US | disclosed |
| US-11266715-B2 | C3A receptor agonists for use against ischemic brain injury, stroke, traumatic brain injury, spinal cord injury and neurodegenerative disorders | PEKNA MARCELA (SE) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11305014-B2 | Modulating permeability of the blood cerebrospinal fluid barrier | C3AR1, CFH, CSF3R | KISS1R 1201/4885IL23R 522/4885 |
| US-20220152205-A1 | MODULATING PERMEABILITY OF THE BLOOD CEREBROSPINAL FLUID BARRIER | C3AR1, CFH, CSF3R | KISS1R 1201/4885IL23R 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.